tiprankstipranks
Trending News
More News >

Newron Pharmaceuticals Advances Phase-III Trials for Schizophrenia Treatment

Story Highlights
Newron Pharmaceuticals Advances Phase-III Trials for Schizophrenia Treatment

Confident Investing Starts Here:

An update from Newron Pharmaceuticals SpA ( (CH:NWRN) ) is now available.

Newron Pharmaceuticals announced the approval of its pivotal Phase-III development program ENIGMA-TRS, which includes two studies to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). The studies, ENIGMA-TRS 1 and ENIGMA-TRS 2, aim to address the unmet medical need for effective treatments in TRS patients by targeting the glutamatergic system, offering a new therapeutic option for those who do not respond adequately to current antipsychotics.

More about Newron Pharmaceuticals SpA

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on developing novel therapies for patients with central and peripheral nervous system disorders. The company is engaged in the development of Evenamide, an innovative treatment for patients with treatment-resistant schizophrenia (TRS) and those with insufficient response to current antipsychotics.

YTD Price Performance: -7.93%

Average Trading Volume: 73,363

Current Market Cap: CHF164.5M

For a thorough assessment of NWRN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1